Company · Biotech and pharma
Oral polymer drugs mimicking bariatric surgery for metabolic disease
Baltimore, OS
Every investor coverage indicates participated in a round Glyscend, Inc. raised.
Companies Glyscend, Inc. acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Thomas Jozefiak | Chief Scientific Officer | Brandon BioCatalyst portfolio |
| Chris Rayner | Gastroenterologist, U of Adelaide | Brandon BioCatalyst portfolio, Glyscend, Inc. team page |
| Ashish Nimgaonkar | President and CEO | Brandon BioCatalyst portfolio |
Stories naming Glyscend, Inc.. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Glyscend has begun a Phase 1 trial in South Australia for its oral polymer diabetes therapy and presented preclinical data; its US$20.5 million Series A was led by Santé Ventures and Brandon Capital.